Scientists Thought Alzheimer's Started in the Brain. They May Have Been Looking in the Wrong Place

For decades, the assumption was simple: Alzheimer’s disease is a brain problem.

It starts in the brain. It unfolds in the brain. And so it should be treated in the brain.

That logic shaped billions of dollars in research and produced a generation of drugs aimed squarely at cleaning out the brain’s toxic buildup.

But a landmark study published in Nature Neuroscience is now pointing researchers toward a deeply unsettling possibility. According to research led by Stanford Medicine neuroscientist Dr. Kati Andreasson, the chain of events that eventually destroys memory and cognition may be set in motion largely by immune cells that live outside the brain entirely.

The key player is a protein called TREM1, found mainly in macrophages, a type of immune cell that circulates throughout the body.

Elevated TREM1 levels in the blood are associated with a significantly heightened risk of Alzheimer’s disease.

And when scientists blocked TREM1 in aging mice, something remarkable happened: the animals performed on memory tests as well as young mice, even though their brains still contained the same toxic protein deposits long considered the hallmark of Alzheimer’s.

That is not a minor tweak to existing theory. That is a rethinking of the disease from the outside in.

How the Study Was Conducted

The Stanford research team, led by senior scientist Edward N. Wilson under Dr. Andreasson’s direction, used a combination of approaches to investigate TREM1’s role in cognitive aging and Alzheimer’s disease.

They worked with mouse models engineered to overproduce amyloid-beta, the sticky protein fragment that accumulates in Alzheimer’s-affected brains.

Some of those mice were genetically modified to lack TREM1 entirely, what scientists call “TREM1 knockout” mice.

The team then compared how these mice performed on standard memory and navigation tests: recognizing previously encountered objects, finding their way through mazes, and retaining spatial information.

They also examined the transcriptomes of peripheral macrophages, essentially taking a snapshot of which genes were active in the immune cells of old mice, old knockout mice, and young mice.

Finally, the researchers studied postmortem human brain tissue from confirmed Alzheimer’s patients to see whether TREM1 patterns in mouse models held up in people.

They found that they did.

Findings From the Study

The results were striking on several fronts.

First, TREM1 levels in the blood rose significantly with age, increasing by roughly 41% in older mice compared to younger animals.

That age-related spike in TREM1 was tied to a broader pattern of metabolic dysfunction in immune cells: macrophages became energy-depleted and shifted into a state of chronic, low-grade inflammation, sometimes called “inflamm-aging.”

Second, when TREM1 was removed from the equation entirely, old mice retained the memory performance of young mice.

Critically, this memory preservation happened even in mice that were still producing excess amyloid-beta and accumulating amyloid plaques in their brains.

That detail matters enormously.

It suggests that the plaques themselves may not be the primary driver of cognitive decline, but rather a downstream consequence of immune dysfunction that originates outside the brain.

Third, when researchers examined human postmortem brain tissue, they found elevated TREM1 levels in immune cells clustered around amyloid plaques, and those elevated levels correlated with greater disease severity.

In other words, the pattern seen in mice appeared in human brains as well.

What Most People Believe About Alzheimer’s Gets More Complicated Here

Here is where the science starts to challenge some very deeply held assumptions.

For more than three decades, the dominant theory of Alzheimer’s centered on amyloid-beta plaques, clumps of a sticky protein that pile up between brain cells long before any symptoms appear.

The theory was intuitive, well-supported by genetics, and it drove the development of a powerful class of drugs designed to clear those plaques from the brain.

Those drugs work. They genuinely strip amyloid from the brain.

The problem is they largely do not restore memory or meaningfully slow cognitive decline in patients, as noted in prior Stanford coverage of why these plaque-clearing drugs fall short.

Spend enough time with that fact and it forces an uncomfortable question: if removing the plaques doesn’t fix the disease, were the plaques really the cause?

The Stanford findings, along with a growing body of supporting research, suggest the answer may be no.

Amyloid-beta, it turns out, is an ancient molecule. It appears in species as evolutionarily distant from humans as coelacanths, fish whose lineage predates the dinosaurs by hundreds of millions of years.

A molecule preserved across 400 million years of evolution was almost certainly doing something useful before it became associated with disease.

And indeed, research shows that amyloid-beta is released in small, controlled amounts whenever neurons fire, possibly playing a role in strengthening connections between brain cells.

The problem may not be the presence of amyloid-beta, but what causes it to accumulate uncontrollably in the first place.

That is where peripheral immune dysfunction enters the picture.

How This Applies to Real Life

This research matters beyond the laboratory for several reasons.

Most immediately, it opens a new category of targets for Alzheimer’s treatment: the immune system as it functions throughout the body, not just inside the brain.

The blood-brain barrier, the selective molecular fence that separates the brain from the rest of the body’s immune activity, makes treating conditions inside the brain extraordinarily difficult.

Drugs often cannot cross it. Targeting macrophages in the bloodstream, however, is something medicine already knows how to do.

If TREM1 in peripheral macrophages is confirmed as a meaningful driver of Alzheimer’s risk, it may be possible to intervene in the bloodstream well before the disease establishes itself in the brain, potentially years before a person ever notices a memory lapse.

That timing is crucial. According to the National Institute on Aging, the brain changes that lead to Alzheimer’s begin accumulating years, sometimes decades, before symptoms appear. Getting ahead of those changes has always been the holy grail of Alzheimer’s prevention.

The Inflammation Connection

The TREM1 findings also add weight to a concept that has been building momentum in Alzheimer’s research: chronic inflammation as a central mechanism of the disease.

TREM1 is, at its core, an inflammation amplifier. When macrophages carry high levels of it, their inflammatory responses become exaggerated and harder to switch off.

Over time, this chronic, low-level immune activation creates conditions that are hostile to healthy brain function, not by crossing into the brain directly, but by altering the brain’s internal environment from the outside.

Think of it like a neighbor leaving their car alarm running indefinitely. The alarm is outside your house, but the noise still disrupts everything happening inside.

The National Institute on Aging’s 2024 Report to Congress on Alzheimer’s disease specifically identified immune system dysfunction as an emerging area of focus, noting that new research points to how faulty immune processes may actively contribute to the development of Alzheimer’s, including the buildup of plaques and tangles in the brain.

The Stanford TREM1 work gives that immune hypothesis a specific molecular address.

Why Age Is Still the Biggest Factor

None of this overturns the most reliable known fact about Alzheimer’s: aging remains the single greatest risk factor.

Nearly one in nine Americans over the age of 65 have Alzheimer’s. For those over 85, the odds rise to roughly one in five.

The TREM1 research actually helps explain why aging and Alzheimer’s are so tightly linked.

With age, macrophages accumulate more TREM1, their metabolism becomes less efficient, and their inflammatory responses become harder to regulate. This age-related immune decline may be precisely the mechanism that tips the brain from normal aging into the territory of disease.

It also helps explain why lifestyle factors tied to inflammation, such as chronic stress, poor sleep, physical inactivity, and diet, consistently appear in research as contributors to dementia risk. They are not random correlations. They may be nudging the same underlying immune system toward the kind of dysfunction that TREM1 amplifies.

What Comes Next

Dr. Andreasson’s team is now actively investigating the specific mechanisms by which inflammatory signals from peripheral macrophages get transmitted to the brain.

That is the next piece of the puzzle, and it is a significant one.

Understanding that communication pathway could reveal additional intervention points, and potentially lead to treatments that work not by attacking the brain’s plaques after the fact, but by quieting the immune system’s alarm signal before brain damage even begins.

According to the NIH’s 2025 Alzheimer’s Disease Research Progress Report, at least 25 new drug candidates developed with NIH funding have now advanced to human trials as of early 2025, with several targeting early-stage biological pathways rather than late-stage symptoms.

The era of only looking inside the brain for Alzheimer’s answers appears to be giving way to something broader, and potentially more promising.

The disease may start with a story your immune system tells, long before your brain ever hears it.

References and Further Reading